Previous in vivo studies have reported caspofungin dose escalation to be effective against Candida glabrata with reduced susceptibility. We hypothesized that higher doses of caspofungin would be effective against invasive candidiasis caused by the more virulent species Candida albicans, including isolates resistant to this echinocandin. Immunocompetent mice were inoculated with one of three C. albicans isolates, including one susceptible and two resistant isolates with different FKS1 hot spot 1 point mutations. Mice received daily caspofungin treatment for 7 days and were then followed off therapy for 2 weeks to assess survival. Kidney tissue and blood were collected, and fungal burden and serum (133)
survival). In contrast, caspofungin doses as low as 1 mg/kg improved survival (85 to 95%) and reduced tissue burden and (133)--D-glucan concentration against the susceptible isolate (ATCC 90028). These data suggest that caspofungin dose escalation for invasive candidiasis may not be consistently effective against resistant C. albicans isolates, and this may be associated with the virulence of the strain.Echinocandins are safe and effective for the treatment of invasive candidiasis. In clinical trials at approved doses, these agents have been shown to have response rates of between 70 and 75% (15,20,25,26). Overall, the toxicity profile of these agents is quite favorable, with reported adverse event rates similar to that of fluconazole and lower than those of amphotericin B formulations (15,20,29). In fact, a recent study demonstrated that daily doses of caspofungin of 150 mg, or three times the recommended daily dose of 50 mg, were safe and well tolerated (3). Similarly, high doses of micafungin have also been shown to be relatively well tolerated, with few toxicities in different patient populations, including patients with hematologic malignancies undergoing stem cell transplantation and children (12,30,31).As is common with most antimicrobials, isolates of different fungal species have developed resistance to echinocandins.